Treatment With UGN-102 in Patients With Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Data From the Phase 3 ENVISION Trial

Utopia: A Phase 3 Trial Of UGN-103, An Intravesical Mitomycin Reverse Thermal Hydrogel For Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Patient Experiences With UGN-102 For Recurrent Low-Grade Intermediate-Risk Non Muscle Invasive Bladder Cancer (LG-IR-NMIBC): Insights For Shared Decision-Making

Duration Of Response To UGN-102 By Age At Baseline Across 3 Clinical Trials In Patients With Recurrent Low-Grade Intermediate-Risk Bladder Cancer

Patient Experiences With UGN-102 For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC): Insights For Shared Decision-Making

UGN-102 Achieves Durable Responses Across EORTC Recurrence Score Groups In Adults With Recurrent Low-Grade Intermediate-Risk NMIBC (ENVISION Trial)

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Long-Term Outcomes of the OPTIMA II Study

Patient-Reported Outcomes Following Treatment of Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer With UGN-102

Duration of Response (DoR) Following Treatment With UGN-102 in Patients With Recurrent, Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer: 18-Month DoR Data From the Phase 3 ENVISION Trial

Psychometric Validaton of a Quality of Life Scale in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment With UGN-102: A Substudy of the Phase 3 ENVISION Trial

Impact of Tumor Burden and Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment With UGN-102: A Subanalysis of the Phase 3 ENVISION Trial

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Results of the Phase 3 ENVISION and ATLAS Studies

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC) With UGN-101, a Mitomycin Reverse Thermal Gel

Home Instillation of UGN-102 for Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3B Trial

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Phase 3 ENVISION Trial: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG-IR-NMIBC) (NCT05243550)

The uTRACT Registry: A Single-Arm, Multicenter, Prospective and Retrospective Registry Study to Evaluate the Real-World Use of UGN-101 in Participants With Upper Tract Urothelial Carcinoma (UTUC) in the United States